Processa 8-K/A Reveals Vidya Going Concern and $175M IPR&D Write-Off
PCSA is trading near its 52-week low of $1.57 (1.9% above the low) on light trading volume (0.1× avg).
Summary
Processa's 8-K/A reveals Vidya's audited financials with a going concern opinion, a $175M IPR&D write-off, and a risk that the $200M PIPE could require cash settlement if stockholders don't approve preferred stock conversion.
Key Events · M&A and Partnerships · PCSA
-
Vidya Audited Financials Show Going Concern
Cherry Bekaert issued a going concern opinion on Vidya's FY2025 financials, citing a $6.1M net loss and accumulated deficit of $6.5M. The opinion states substantial doubt exists about Vidya's ability to continue as a going concern.
-
$175M Acquired IPR&D Expense
The pro forma combined statement of operations for FY2025 shows a $175.0M acquired in-process research and development expense, contributing to a pro forma net loss of $196.4M.
-
Series A Preferred Stock Cash Settlement Risk
If stockholders do not approve conversion of Series A Preferred Stock within nine months of issuance, holders can demand cash settlement at fair value. Management states this could materially affect operations and financial condition.
-
H1 2026 Vidya Net Loss of $30.1M
Vidya's unaudited H1 2026 financials show a $30.1M net loss, driven by a $27.3M non-cash increase in SAFE liability fair value as the estimated equity value rose to $175M ahead of the merger.
Analysis · PCSA · Life Sciences
This amendment to the July 29 merger 8-K delivers the first audited financials for Vidya Therapeutics, and they carry a going concern opinion from Cherry Bekaert. The pro forma combined statements show a $196.4M net loss for FY2025, driven largely by a $175.0M acquired in-process R&D expense. The filing also discloses that the $200M PIPE proceeds are contingent on a stockholder vote to convert Series A Preferred Stock — if that vote fails, holders can demand cash settlement at fair value, which management says could materially harm operations. The going concern language and cash settlement risk are new material disclosures that go beyond the original merger announcement.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $1.57 to $14.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.